Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
Status: APPROVED_FOR_MARKETING
Study type: EXPANDED_ACCESS
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Abemaciclib
Sponsor: Eli Lilly and Company